One mechanism -Neural line-art figure of a woman reaching outmultiple indications

By targeting peripheral immune pathways to activate a common therapeutic mechanism regardless of disease origin, IBC-Ab002 is being developed for multiple neurodegenerative diseases, including Huntington’s and Parkinson’s diseases, and other forms of age-related dementia.

Development pipeline

ProgramIndicationStatus

IBC-Ab002

Alzheimer's disease

DiscoveryPreclinicalPhase 1Phase 2Phase 3

IBC-Ab002

Parkinson's disease*

DiscoveryPreclinicalPhase 1Phase 2Phase 3

IBC-Ab002

Huntington's disease*

DiscoveryPreclinicalPhase 1Phase 2Phase 3

*Huntington's disease and Parkinson's disease are Phase 2b ready, leveraging the Phase 1b package from the Alzheimer's disease program.

Preview of the Nature Medicine Phase 1b article on IBC-Ab002
Nature Medicine

Published in Nature Medicine

Phase 1b study - clinical data

The randomized, double-blind Phase 1b study of IBC-Ab002 in Alzheimer's patients has completed with favorable safety and exploratory biomarker signals. A Phase 2b study in early Alzheimer's disease is planned for H1 2027.

Safety

Favorable safety signals were reported in the completed Phase 1b study.

Exploratory biomarkers

Encouraging biomarker signals support continued investigation of this approach.

IBC-Ab002 in Alzheimer's disease

Indications

Alzheimer's disease

~32 million people living with Alzheimer's dementia worldwide

Parkinson's disease

>8.5 million people living with Parkinson's disease worldwide

Huntington's disease

~2.7 per 100,000 people worldwide (5.7 per 100,000 in Europe, North America and Australia)

Age-related cognitive decline

~15.6% of adults over 50 live with mild cognitive impairment

Sources

  1. Gustavsson A. et al. Global estimates on the number of persons across the Alzheimer's disease continuum. Alzheimer's Dement. 19, 658-670 (2023).
  2. World Health Organization. Parkinson disease fact sheet (2023).
  3. Pringsheim T. et al. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov. Disord. 27, 1083-1091 (2012).
  4. Bai W. et al. Worldwide prevalence of mild cognitive impairment among community dwellers aged 50 years and older: a meta-analysis and systematic review of epidemiology studies. Age Ageing 51, afac173 (2022).